CD274 and head and neck squamous cell carcinoma: The subsequent phase II study (HAWK) evaluated durvalumab monotherapy in patients with PD-L1-high R/M HNSCC defined as TC ≥ 25% and demonstrated an ORR of 16.2% and a 12-month survival rate of 33.6% [30].